1. Scrip

Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK

 
• By Sten Stovall

Gedeon Richter has finally had its antipsychotic cariprazine approved in the EU for treating schizophrenia - but its delay to market could dampen demand for the drug unless it can differentiate itself from rivals.

Schizophrenia
Gedeon Richter's Cariprazine Wins EU OK For Treating Schizophrenia • Source: Shutterstock

Gedeon Richter PLC 's antipsychotic cariprazine – which has EU approval following a positive regulatory assessment in May - is expected to start launching across the EU on a country by country basis from mid-2018 when pricing and reimbursement has been finalized, analysts say.

But to drive its uptake, Hungary-based Gedeon and its European market partner Recordati Industria Chimica & Farmaceutica SPA of Italy will need to differentiate their product from other well-established - and genericized -

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.